SLGL | tickerfilter.com

Fundamental analysis

30%

Profitability 25%

Dept financing 10%

Liquidity 50%

Performance 35%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

4.64%

1 Month

56.15%

3 Months

0.25%

6 Months

32.03%

1 Year

-7.39%

2 Year

-77.57%

Key data

Stock price

$0.81

P/E Ratio

0.00

DAY RANGE

$0.71 - $0.83

EPS

-$1.44

52 WEEK RANGE

$0.33 - $1.65

52 WEEK CHANGE

$13.96

MARKET CAP

19.470 M

YIELD

N/A

SHARES OUTSTANDING

27.858 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-29-2025

BETA

2.82

PUBLIC FLOAT

AVERAGE 10 VOLUME

$264,260

AVERAGE 30 VOLUME

$395,543

Company detail

CEO: Alon Seri-Levy
Region: US
Website: sol-gel.com
Employees: 50
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sol-Gel Technologies Ltd. focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system. Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris, Epsolay, SGT-210, and Erlotinib, Tapinarof, and roflumilast are the company's lead product candidates.

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210

SLGL - Sol-Gel Technologies Ltd.

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.